KONIKU

Koniku is a synthetic biotechnology startup that merges biology with technology to create 'smell cyborgs', devices capable of detecting and analyzing volatile organic compounds in the air. These devices, which combine live cells with silicon, are designed to function as sensors, amplifiers, and biological signal processors. The company's ultimate goal is to place these devices in 10 million homes within the decade, with the aim of diagnosing diseases and maintaining health in real-time.

Koniku's business model revolves around creating a marketplace for individual health management. By providing real-time health data, they empower individuals to take charge of their own health. The company operates in the biotechnology and health tech markets, serving clients ranging from individual consumers to Fortune 500 companies.

The company generates revenue by selling their 'smell cyborgs' and through their Koniku Technology Integrator Ecosystem (KTIE). The KTIE is a community of solutions developers, fostering businesses from startups to large corporations. This ecosystem allows for the integration of Koniku's technology into various applications, creating additional revenue streams.

Koniku's unique approach to health tech involves feeding the data collected by their devices into a machine learning backend. This allows the company to classify and create value from all smells that impact human life, creating a proprietary data set that can be leveraged for various applications.

Keywords: Synthetic Biotechnology, Smell Cyborgs, Health Tech, Individual Health Management, Volatile Organic Compounds, Silicon, Koniku Technology Integrator Ecosystem, Machine Learning, Proprietary Data Set, Fortune 500.